anonymous
Guest
anonymous
Guest
Last month, AstraZeneca said it would cut $1.1 billion in annual costs, zeroing in on sales and administrative expenses for a big part of those savings.
Now, the U.K.-based company’s sales operation in the U.S. is feeling the effects.
AstraZeneca cut its contract salesforce from Publicis Touchpoint Solutions, the company confirmed in an emailed statement Tuesday, and is reviewing its AstraZeneca sales staffing as well.
Publicis handles AstraZeneca brands in a variety of therapeutic areas, AstraZeneca spokeswoman Abby Bozarth said. The clinical educator team will also see some cutbacks.
“We flexibly shape our selling teams to fit the realities of the marketplace and maximize opportunities for both our growth and future brands,” Bozarth said.
Publicis sales reps on the AstraZeneca force said the cutbacks would hit 1,600 contract employees, largely in diabetes, although the respiratory team and the Movantik force would also see some reductions. The sources spoke on condition that they remain anonymous.
The Publicis cuts take effect June 30. They were announced via conference call Monday.
I was a DSS4 that was just laid off from PTS/AZ. I was told I will be placed in front of the hiring manager for this contract. This is probably why everything has been put on hold...to allow displaced reps from another publicis contract